Blinatumomab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 35mcg
Reference Brands: Blincyto (USA/EU)
Category:
Oncology Cancer Care
Blinatumomab is a bispecific T-cell engager (BiTE) antibody used in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). It works by connecting T-cells to cancerous B-cells, enabling the immune system to destroy them. Marketed under the brand name Blincyto, it is available as a powder for infusion (35 µg or 38.5 µg per vial). It is used in both adults and children with relapsed, refractory, or minimal residual disease–positive ALL.
Blinatumomab is available in Injection
and strengths such as 35mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Blinatumomab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Blinatumomab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing